Replies to post #512739 on NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Will be interested to see what FDA says about this heavily manipulated trial.

Will be interesting to see if you will stay around to inform us about it.

Odds are good!

[SkyLimit2022]

Thank you for reminding us of all the publicity available evidence of the FDA’s likely support of DCVax and other emerging immunotherapy technologies.

The FDA approved the trial to commence, approved the trial to resume after its halt years ago, and the trial was successfully completed at 94 sites worldwide.

There is evidence that the FDA does and will have a favorable view of the DCVax P3, and no evidence to the contrary.

The FDA director said:

"Now we are in the era of immunotherapy"
-Richard Pazdur, MD

"Often, novel agents are so obviously superior to standard of care that no patient would participate in a randomized trial knowing that somebody else might get the experimental drug
-Richard Pazdur, MD

"There's also been a revolution in tumor immunology. Before, in my early career, tumor immunology was looked at kind of as black magic, as witchcraft. Now it's accepted."
-Richard Pazdur, MD

"When we make a decision about approving a drug, it has to be patient centered. It can't be about the
regulations"
-Richard Pazdur, MD

https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext

Fact check: The FDA and NIH work very closely together. Highly reputable licensed professionals have vetted the immunotherapy research of Dr. Liau, I would recommend that you research and study for yourself the recent 590 million dollar grant that was awarded to UCLA. The U.S. government NIH grant is funded by tax dollars and is public record for anyone who wants to see it. Within its many many pages, you will find many professionals who have reviewed the immunotherapy work of Dr. Liau. Verify it for yourself.

The NIH peer-reviewed grant is the source of funding being used today to dose patients with DCVax-L and Keytruda.

clinicaltrials.gov/...

Department of Neurosurgery Chair Linda M. Liau, MD, PhD, MBA, was a leading recipient of NIH grants – No. 3 in the nation within the discipline.

“It's the stamp of approval from the NIH, because these types of grants are so rigorously peer-reviewed,” Dr. Liau says. “People get funded based on the strength of the science and that, itself, is very powerful in terms of showing that our research is scientifically valid and meaningful and hopefully will lead to future treatments.”

So once again—the NIH for example, is a much better source than I am or that anyone on social media is or anyone on a stock message board. Researching the peer review of a large recent government grant is an example of research that is more reliable than a stock message board is. Anyone can go look at the grant for themselves and review the professional vetting of its recipients.

NIH and the FDA tell us that they are well-coordinated they assert that work closely together on the development of new technologies.

connect.uclahealth.org/...

[Roman516]

Since you appear not to be invested in NWBO, why even bother since there is no point. Detailed investigations have indicated that NWBO has been under attack for considerable amount of time by a number of individuals and other entities.
Many people have addressed your comments already and with detailed rebuke.
The real issue is that external forces are diligent to try to keep NWBO down but given that fact that DCVax-L works and requires the right facilities to ready to deploy is the main focal point. Hence, NWBO presses onward towards the goal of sucess.